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Dimitris Bertsimas1, David Czerwinski2* and Michael Kane3Abstract
We present a methodology for using health insurance claims data to monitor quality of care. The method uses a
statistical model trained on the quality ratings of a medical expert. In a pilot study, the expert rated the quality of
care received over the course of two years by 101 diabetes patients. A logistic regression model accurately
identified the quality of care for 86% of the patients. Because the model uses data derived from patients’ health
insurance claims it can be used to monitor the care being received by a large patient population. One important
use of the model is to identify potential candidates for case management, especially patients with complicated
medical histories.
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Researchers have demonstrated in recent years that
many patients in the United States do not receive high-
quality health care (Schuster et al. 1998; Corrigan 2001).
In this paper, we address the problem of identifying, in
an automated fashion, diabetes patients who may be re-
ceiving poor care so that interventions can be arranged
to improve their care. We measure quality of care with
an expert-trained statistical model using variables de-
rived from medical insurance claims data.
We focus on patients with diabetes for several reasons.
First, diabetes is a widespread, costly disease. Over 25
million Americans are diabetic – about 8% of the US
population – and the annual cost of diabetes is esti-
mated at $174 billion (Centers for Disease Control and
Prevention 2011). Second, there are well established
guidelines for its treatment, and third, limiting the study
to one disease minimizes variations in care from patient
to patient that aren’t related to quality.
We are interested in identifying individual patients
with poor care in “real-time” so that interventions can
be arranged to improve their care. This intervention-
oriented patient-centered view is somewhat distinct from
previous studies of quality of care. Existing studies have* Correspondence: david.czerwinski@sjsu.edu
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in any medium, provided the original work is pmeasured quality in order to assess the US healthcare
system (Schuster et al. 1998; Corrigan 2001; Berwick
2002; Davis et al. 2007; Agency for Healthcare Research
and Quality 2006; Schoenbaum et al. 2007; Asch et al.
2004; Leatherman and McCarthy 2002; Hayward 2007);
to study health plans (Wholey et al. 2003a, Wholey et al.
2003b); to identify practices and factors that improve
quality (Heisler and Wagner 2004; Solberg et al. 2008;
Hanchate et al. 2010); to provide rankings of doctors
and healthcare facilities (United States Department Of
Health and Human Services 2012; Hofer et al. 1999;
Gandhi et al. 2002; Li et al. 2007; Shwartz et al. 2009);
and to rate providers for “pay-for-performance” type re-
imbursement (Pham et al. 2007; Scholle et al. 2009;
Romano and Mutter 2004).
We want to emphasize that the goal of identifying
poor care is not to assign blame for it. Poor quality care
can be caused by the physician or the patient (or per-
haps the combination of a particular patient with a par-
ticular physician) or external factors beyond either’s
control. The purpose of the model is to identify patients
receiving poor care so that case management can be ar-
ranged. The case management might very well focus on
improving the patient’s compliance with care.
To measure quality, we use a statistical model trained
on a set of patients whose care was assessed by a phys-
ician. The variables in the model are derived from the
patients’ insurance claims data. We use claims datais an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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able, timely source of information documenting the care
a patient has received. With them, the care received by a
large population of patients can be monitored on an on-
going basis. Other methods of measuring quality, such
as reviewing paper medical records, may be more thor-
ough but they do not scale to large patient populations
because of the manual labor involved.
That is not to say that claims data are without draw-
backs. They lack clinical details such as symptoms, test
results, and severity of disease. They reflect little about the
patient’s quality of life. Though overall the coding of
diagnoses and procedures in claims data are accurate, they
can sometimes be vague (Kashner 1998). When there are
multiple diagnoses during a single visit some may not be
captured. Minor non-monetized procedures – such as
counseling a patient to stop smoking – are usually not
recorded.
Our statistical models measure the quality of the
process of care (Brook et al. 2000; Brook and Cleary
1996). In trying to improve the care for a particular pa-
tient, structural aspects of care are less relevant since
they are fixed over the short term. Ideally, we would
measure outcomes of care but outcomes are difficult to
infer from claims data since lab results, symptoms, etc.
are not captured (Wennberg et al. 1987). For example,
an insurance claim may record that a diabetes patient
had a glycated hemoglobin test, but it will not record
the results of the test. Whether the patient’s glucose
level is improving or not cannot be determined. Further-
more, because we have data only over a two-year period,
long-term outcomes cannot be measured. Though we
didn’t instruct the physician rating the quality of care to
look specifically at process of care, that is what de facto
was available to him.
Of course, process measures of quality of care for dia-
betes patients exist in the form of the guidelines of the
American Diabetes Association (2007). These guidelines
have been developed based on the best available evi-
dence and, where conclusive evidence is still lacking,
consensus of expert opinion. Yet, many aspects of a pa-
tient’s care are beyond the purview of the guidelines.
Also, using clinical guidelines to measure quality of care
for patients with multiple diseases can be problematic
because guidelines focus on the optimal treatment of a
single condition (Kerr et al. 2001). For an individual with
several coexistent disorders the treatment demands for
one disease may conflict with recommendations for
others. Finally, intangible aspects of care might be diffi-
cult to capture in written guidelines.
By having a physician review the claims data for our
study set, we obtain a holistic view of the patient’s care.
The physician can consider not only the care they re-
ceived for their diabetes, but also for comorbidities. Hecan examine the patient’s overall course of care, includ-
ing routine preventive care. Nevertheless, the diabetes
treatment guidelines are relevant and below we discuss
how compliance with the guidelines correlated with the
physician’s assessment of care.
Though we have built a statistical model to identify
poor quality care, we do not claim that the model defines
poor care. Identifying poor care is not equivalent to de-
fining it. For example, consider the statistical models
used by credit card companies to identify fraudulent pat-
terns of transactions. The use of a credit card in rapid
succession at gas stations may be a red-flag that the card
has been stolen. But that is not to say that it is wrong
for a person to use their own credit card in rapid succes-
sion at gas stations. It is simply a fact that such behavior
is correlated with fraud. In the same way, if our
statistical models incorporate the use of narcotics as a
red-flag for poor care this does not mean that all uses of
narcotics are inappropriate. It simply means that there is
a correlation between the use of narcotics and poor care.
An advantage of our approach is that it doesn’t rely on
an explicit definition of quality.
Methods
From a large health insurance claims database, we ran-
domly selected 101 diabetes patients aged 35–55 with
healthcare costs between $10,000 and $20,000 over the
two-year study period (September 1, 2003 to August 31,
2005). A patient was considered diabetic if they had ei-
ther two outpatient diagnoses of diabetes or one in-
patient diagnosis of diabetes over the two-year period.
The lower bound on the cost ensured that each patient
had enough claims data so that the reviewer could make
an assessment of the quality of care they received. Like-
wise, the upper bound ensured that no patient’s claims
record was so lengthy that it would be impractical to
review.
We attempted to oversample patients who might have
received poor care to ensure their adequate representa-
tion in the sample. Of course, without a measure of the
quality of care at the outset, we couldn’t do this exactly.
As an approximation, we scored the patients based on
the presence of hemoglobin HbA1c tests, lipid profiles,
and eye exams in their claims data (Weiner et al. 1995).
Scores could range from zero (none of the above proce-
dures was performed) to three (all three procedures were
performed). We then drew a stratified random sample
by score, oversampling the lower scores.
The claims data consist of all insurance-based health
care utilization for the patients in the study and com-
prise medical services and pharmaceutical prescriptions.
Claims for medical services record the date of service,
the provider, diagnoses, procedures performed, and the
amount paid. Claims for prescription drugs record the
Table 1 Summary of the physician’s quality ratings and
his confidence in them
Low confidence High confidence
Low quality 5 17
Average quality 16 25
High quality 3 35
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ician, the drug, the number of days of supply, and the
amount paid.
One of us, physician Dr. K, reviewed the claims re-
cords for each of the 101 patients and scored the quality
of care they received. He rated the care on a three-point
scale: poor, average, or good. He also rated his confi-
dence in his assessment on a two-point scale: confident
or not confident. In addition, he wrote a one-paragraph
summary for each patient describing their condition and
the care they received and noting aspects of their care
that influenced his rating. These narratives were used
later in developing variables for the statistical model.
Dr. K reviewed and rated 30 additional patients (not
used to develop the model) which were used to validate
the model. A second physician, Dr. L, also rated the 30
patients in the validation set independently of Dr. K.
Having a second physician rate the patients allowed us
to assess the extent to which the models reflected beliefs
about quality specific to Dr. K. The contrast between the
backgrounds and experience of the two doctors is
marked. Dr. K was trained in the United States and has
over 30 years of experience, whereas Dr. L was trained
abroad and had recently completed his residency.
Model development and evaluation
Our dependent variable is quality of care. Since we are
mainly concerned with identifying poor quality care, we
combined patients who received “average” or “good”
care into a single group which we will refer to as the
good care group. A value of 1 for the quality of care vari-
able was used to indicate good quality care, a value of 0
for poor. Incorporating information about the physician’s
confidence did not lead to more accurate models nor
did disaggregating the good care group into average care
and good care.
Though the number of independent variables that we
explored is large, we provide a brief overview of them
here. The full list of variables with their definitions can
be found in the Appendix. The variables may be catego-
rized into those related to diabetes treatment (e.g.
the number of glycated hemoglobin tests performed),
patient demographics (e.g. age and gender), healthcare
utilization (e.g. total number of office visits), markers of
good care (e.g. the performance of a mammogram for fe-
males), markers of poor care (e.g. the administration of a
B12 injection), providers (e.g. number of different pro-
viders), claims (e.g. total number of claims), and pre-
scriptions (e.g. number of prescriptions and changes in
prescriptions).
All of the independent variables are computable dir-
ectly from the patients’ claims data. Most of the vari-
ables capture general aspects of care but some are
specifically inspired by the physician’s comments in hisnarratives. Yet we avoided defining variables that would
only apply to one or two patients in the sample since no
statistically meaningful statements could be made about
such variables. For example, one patient was judged to
have received poor care because she was treated over a
long period with an antibiotic for a urinary tract infec-
tion but without regular gynecological exams. (When
she finally did have a gynecological exam uterine cancer
was discovered.) As this situation arose with only one
patient, we would not be able to statistically assess the
value of a quality indicator such as “on antibiotic for a
urinary tract infection without gynecological exams.”
We restricted our attention to variables that would
apply more broadly.
We modeled the data using logistic regression. To as-
sess a model’s accuracy we computed the percent of pa-
tients that it classified correctly (i.e. that matched the
physician’s classification). Bootstrap resampling was used
to estimate out-of-sample accuracy during model devel-
opment due to the small number of observations. 500
bootstrap trials were used, adjusting for bias as discussed
in Hastie et al. (2001). After model selection and fitting
was complete we performed a true out-of-sample test on
the 30 hold-out cases.
Because the majority of patients received good care,
the simplest predictive model would be to blindly clas-
sify each patient’s care as good; 78% of patients would be
accurately classified. This serves as a useful baseline
against which to assess our model. Another natural base-
line model is one using only variables based on the dia-
betes treatment guidelines. A logistic regression model
based on only these variables also had an accuracy of
78%. Comparing the performance of our model to such a
model reveals whether incorpating aspects of care be-
yond the guidelines is of value in identifying poor care.
We used a stepwise procedure to develop the model.
We started with an empty model and continued to add




Table 1 shows a summary of the physician’s quality-of-
care ratings for the 101 patients. 78% of the patients re-
ceived average or better care. The physician had high
confidence in 76% of his assessments. Most of the cases
Table 2 Percent of patients receiving eye exams, glycated
hemoglobin tests, and lipid profiles by quality rating
Poor Average Good
Percent receiving eye exams 25 34 43
Percent receiving hemoglobin tests 40 53 62
Percent receiving lipid profiles 50 55 54
Table 3 Dr. K’s classification compared with the model’s
Model
Dr. K Poor Good
Poor 12 10
Good 4 75
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(χ2=10.6, p = 0.005).
Here is an example descriptive paragraph written by
the physician for a patient who received good care:
45 year old type 2 diabetic on metformin and
glyburide. Also took lexapro and ambien regularly,
and crestor. He carried a diagnosis of sarcoid for first
part of the analysis period and was treated with
prednisone for a while-that’s appropriate for sarcoid,
even in a diabetic. He was also appropriately covered
with fosamax initially. He seems to have changed
PCP’s in mid cycle. Had first labs 2/04. Had only one
ER visit for a forehead laceration. He had a stress test
5/16/05 for chest pain, followed by a catheterization
on 5/27/05. Apparently nothing worrisome was found.
Despite sarcoid diagnosis he had no chest X-rays or
pulmonary function tests. Had one podiatry visit in
June ’05. No home testing, no eye exams. Overall,
given pulmonary and mental health comorbidities,
care looks good with high confidence.
To determine how much variability there was in dia-
betes care among the patients in the sample we assessed
the compliance of the patients’ care with three compo-
nents of the diabetes treatment guidelines (eye exams,
glycated hemoglobin tests, and lipid profiles).
36% of the patients in the sample had evidence of at
least one eye exam. Since a patient may have had separ-
ate vision insurance, an eye exam may not have been
recorded in the health insurance claims data even if one
was performed. Therefore, this number should be
treated as a lower bound on the percent of patients
who had eye exams. 54% had evidence of a glycated
hemoglobin test and 54% had evidence of a lipid profile.
However, when laboratory tests such as these are
performed in a hospital, the type of test is often not
coded in the insurance claims data. 59 patients in the
data set had instances of non-specified diabetes testing
performed in hospitals. If we are generous and assume
that when testing was done it was the correct tests
(according to the guidelines), then the compliance would
be 91% for hemoglobin tests and 92% for lipid profiles.
Alternately, if we limit ourselves to the 36 patients all of
whose lab work was performed outside of hospitals, 75%
had hemoglobin tests and 78% had lipid profiles. The
correlation between the performance of hemoglobin
tests and the performance of lipid profiles was 0.46.
Table 2 shows the compliance with each component of
the diabetes treatment guidelines for the poor, average,
and good care groups. For example, of the patients
whose care was rated poor, 26% received eye exams
whereas 50% of the patients whose care was rated good
received eye exams. For eye exams and hemoglobintests, compliance tends to increase as the physician’s rat-
ing of quality increases. The differences are not statisti-
cally significant however (p= 0.95).
Logistic regression model
The logistic regression model incorporates the variables
StartedOnCombination, HemoglobinTest, and Acute-
DrugGapSmall. StartedOnCombination is an indicator
variable with a value of 1 indicating that the patient’s drug
therapy for diabetes started with a combination of drugs,
rather than a single drug. HemoglobinTest is a count of
the number of glycated hemoglobin tests the patient had.
AcuteDrugGapSmall is the fraction of refills for acute
drugs that followed the exhaustion of the previous pre-
scription by a gap of between 1 and 30 days.
The regression equation is:




In the model, polypharmacy (StartedOnCombination)
is penalized through its negative coeffient. Glycated
hemoglobin tests are rewarded, which is fitting as they
are recommended by diabetes treatment guidelines. And
finally, the variable AcuteDrugGapSmall has a negative
coefficient. A high value for this variable indicates the
repeated use of an acute drug. Such repeated use may
indicate that the physician’s diagnosis or choice of drug
is incorrect.
The model has an in-sample accuracy of 86% and an
estimated out-of-sample accuracy of 84%. The model
correctly identified 12 of the 22 cases of poor care for a
sensitivity of 54%. Only four patients out of the 79 who
received good care were misclassified, for a specificity of
95%. The agreement between Dr. K and the model is
summarized in Table 3.
Table 4 Out-of-sample comparison of Dr. K’s
classifications with the model
Model
Dr. K Poor Good
Poor 6 5
Good 1 18
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can be used to adjust the trade-off between sensitivity
and specificity. The accuracy of 86% was obtained by
setting the cutoff value between poor care and good care
at the level which maximizes overall accuracy. Figure 1
shows the range of sensitivity and specificity that can be
obtained by our model by varying the cutoff. A higher
sensitivity will result in a higher percentage of poor care
cases being correctly identified. Though in practice,
maintaining a high specificity may be more important.
Out-of-sample validation
Because the patient mix is different for the hold-out
sample of 30 than for the original training data, the rele-
vant baseline accuracy for comparison is not 78% but
63%. (Direct comparison to the estimated out-of-sample
accuracy rate therefore isn’t meaningful, though compar-
isons of sensitivity and specificity are.) When applied to
the hold-out sample, our model has an accuracy of 80%,
17 percentage points above the baseline. The model has
an out-of-sample sensitivity of 54% and specificity of
95%. The out-of-sample agreement between Dr. K and
the model is summarized in Table 4.
Table 5 shows the level of agreement between the two
doctors’ ratings on the 30 out-of-sample cases. The doc-
tors were in complete agreement on 12 of the 30 pa-
tients. On an additional 14 their ratings differed by aFigure 1 Trade-offs between sensitivity and specificity obtainable usisingle level (e.g. a case rated as good by one doctor was
rated average by the other). In only four cases was there
a complete divergence of ratings, with one doctor rating
the care as good and the other doctor rating it as poor.
In three of these four cases, Dr. K was the one who rated
the care poor and in all three cases Dr. K’s comments in-
dicated that he felt the patient was on an inappropriate
combination of drugs. Dr. L did not make comments
about drug combinations for any of the 30 patients.
Here are sample paragraphs written by the two physi-
cians for one of the patients who both doctors felt re-
ceived good care with high confidence. We begin with
Dr. L’s assessment:
This patient was closely monitored for blood glucose,
had ophthalmology follow up, multiple urinalysis, on
an ACE ARB. Treated with multiple oral agents. Seen
for foot problems. Might have benefited from a
platelet inhibitor, but otherwise high quality care.ng the logistic regression model.
Table 5 A comparison of the two physicians’ ratings
Dr. L
Dr. K Poor Average Good
Poor 4 4 3
Average 6 5 2
Good 1 2 3
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She is a Type 2 diabetic on several oral agents. She
also had regular prescriptions for an ACE inhibitor
and for diabetes testing supplies. Had regular
prescriptions for nortriptyline (antidepressant) and
lorazepam with no formal mental health care, but I
saw no sign of excess care or other issues that would
indicate active mental health problems. She had eye,
gyn and podiatry care and a mammogram, and
regular visits with her PCP. She had an ER visit for
abdominal pain in July ’04 with a prompt follow up
visit afterward with her PCP. There were no
hospitalizations. Care was orderly and looks to be
good care with high confidence.
Neither doctor tended to be more negative in their over-
all ratings than the other. Dr. K rated 11 patients’ care as
poor, 13 as average, and six as good. Dr. L rated 11 pa-
tients’ care as poor, 11 as average, and eight as good.
The doctors also provided confidence scores for their
ratings. Dr. K rated his confidence as high for 25 of the
patients, Dr. L for 21 of the patients. Since Dr. K has
more experience reviewing claims data, this difference is
not surprising. The doctors were jointly confident in
their ratings of 18 of the patients. Their quality ratings
were in complete agreement on nine of these 18 pa-
tients, a rate marginally better than for the whole set of
30 patients. They still reached opposite conclusions in
three cases.
Our model performs only modestly when compared
with Dr. L’s ratings. It has an accuracy of 67% in
matching Dr. L’s ratings, with a sensitivity of 36% and
specificity of 84%.
Comment
We have demonstrated that an expert-trained statistical
model using health insurance claims data can discrimin-
ate between the quality of care patients receive. Further-
more, only a simple model is required to capture
approximately half of the cases of poor care while
maintaining a low false-positive rate.
Although an accuracy of 86% may not sound terribly
high, in the context of case management even this level
of accuracy can be quite beneficial. A key challenge in
case management is identifying patients to intervenewith, and patients receiving poor care are ideal candi-
dates. Suppose a case management company had 1000
diabetes patients, half of whom were receiving poor care.
If a case manager blindly selected patients from this
pool, they would waste half of their time on patients
already receiving good care. On the other hand, suppose
our model was applied to the 1000 diabetes patients and
only those identified as receiving poor care were passed
on to the case manager. With a sensitivity of 54%, the
model would correctly identify 270 poor-care patients as
such. With its specificity of 95%, the model would incor-
rectly classify 25 patients receiving good care.
Thus, the model would identify a total of 295 patients,
270 of whom actually were receiving poor care. Working
from this “enriched” pool of patients, the case manager
would waste little time on patients receiving poor care.
Of the 295 patients, 92% would be receiving poor care –
a significant improvement over the 50% rate if the pa-
tients were chosen blindly.
The key to the success of the model is not its sensitiv-
ity, which at 54% is admittedly modest. The key is the
modest sensitivity coupled with a very high specificity so
that cases of good care are filtered out. The model will
in fact miss many cases of poor care. But a successful
case management strategy need not involve identifying
all the cases of poor care, it must simply identify enough
to keep the case managers efficiently engaged.
Though we have focused on the use of logistic regres-
sion to classify patients, in practice the fitted probabil-
ities could be used directly as numeric quality scores.
For instance, the scores could be used to prioritize
patients for case management. Rather than treating
patients in the poor-care group as homogeneous, case
managers could begin with the patient whose quality
score was the lowest. Next, the patient with the second
lowest quality score, and so on. In this way, resources
would be focused first on the patients who may be the
likeliest to be receiving poor quality care.
During the exploratory phase of model development,
one unexpected relationship was revealed. A pattern
emerged of an inverse relationship between the quantity
of care ond the quality of care. There could be several
reasons for this. For example, the more interactions a
patient has with the health-care system the more oppor-
tunities there are for a mistake or other error to occur.
An alternative explanation could be that some patients
require so much care because the care they are receiving
is poor: that is, the care is not making them better and
so they continue to seek more care.
One limitation of our pilot study is that it only in-
cluded quality ratings from two physicians. The lack of
strong agreement between the two physician’s ratings
underscores the fact that in a production setting, our ap-
proach would be best served by a panel of reviewers.
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model could also be improved over time using input
from the case managers. If a case manager using the
model disagrees with the rating for a particular patient,
they could record their own rating. As such ratings accu-
mulated in a database, the model could then be re-fit. This
approach could be a cost-effective way to create much lar-
ger training data sets with minimal additional overhead.
Note that the use of case managers might tilt the outcome
being measured from “quality of care” to “potential for
intervention,” which is not necessarily undesirable.
There are several characteristics of the patients in our
study that may limit the generality of the model. The pa-
tients are all insured, and this is necessary because the
method relies on electronic insurance claims data. The
patients are between the ages of 35 and 55. The general
approach would apply to patients outside this range,
though the specific model may change. The patients
have relatively high health care costs. It may be difficult
to apply this method to patients below a certain cost
threshold, since the sparsity of the claims data may not
provide enough information on which to base a judg-
ment of quality. Although high-cost patients are of the
most interest to insurers implementing case management,
a specific weakness of this methodology is its insensitivity
to evaluating the quality of care received by low-cost pa-
tients. A final limitation of the study is that we have used
a relatively small sample size. More data, coupled with a
panel of physician reviers as discussed above, will lead to
more accurate and more generalizable models.
Appendix
Full list of variables
The variables we developed for our models are listed
below, grouped into the following categories: diabetes
treatment, patient, utilization, ratios, markers of good care,
markers of poor care, providers, claims, and prescriptions.
Diabetes treatment
The following variables are based on the guidelines for
the treatment of diabetes or otherwise related to diabetes
care.
EyeExam The number of eye exams. Note that this vari-
able is hampered by the fact that some people may have
visits with eye doctors that are not covered by their in-
surance or are covered by a different insurance plan.
HemoglobinTest The number of glycated hemoglobin
tests.
LipidProfile The number of lipid profiles.
GenericLab The number of times unspecified lab work
was performed (generally at a hospital where the details
of the lab work are not recorded as carefully as for out-
patient lab work). Multiple tests performed on the same
day are considered as one occurrence.AnyLab The number of times any of the following lab
work was performed: glycated hemoglobin tests, lipid
profiles, or unspecified lab work.
DiabetesLab This variable is similar to AnyLab with two
differences: the diagnosis recorded with the lab work
must be diabetes, and a broader range of lab work is in-
cluded. The included lab work is: glycated hemoglobin
tests, lipid profiles, unspecified lab work, hemoglobin
tests, metabolic panels, urine microalbumin tests, and
serum creatinine test.
GlucoseSupplies The number of times glucose testing
supplies were ordered.
AceInhibitors The number of prescriptions for ace
inhibitors.
AceInhibitorDays The number of days for which the
patient had ace inhibitors prescribed. This may be a
more accurate measure than the number of prescrip-
tions, since prescriptions can vary in length.
ARBs The number of prescriptions for angiotensin II re-
ceptor blockers.
Patient
The following variables reflect demographic information
about the patient or about the patient’s claims data.
Age the patient’s age.
Female 1 if the patient is female, 0 otherwise.
Diabetic 1 if the patient is diabetic. (After reviewing
each patient’s claims data, in the physician’s opinion a
handful of patients in the study were not actually dia-
betics but were included due to spurious coding.)
DrugsMissing An indicator variable which is 1 if all
pharmacy claims for the patient were unavailable.
DiseaseCount The number of chronic diseases that the
patient had.
Anxiolytics The number of prescriptions for anxiolytics.
Antidepressants The number of prescriptions for
antidepressants.
Pain 1 if the patient had any coding for pain, 0 otherwise.
MedianMonthlyCost The patient’s median monthly
health-care cost over the study period.
CostDerivative The slope of the patient’s monthly costs
over the study period. This was calculated for each patient
by fitting a linear regression of monthly cost versus time
(indexed 1,…,24 for the 24 months in the study period) and
extracting the coefficient for time.
CostSecondDerivative The second derivative of the pa-
tient’s monthly costs over the study period. This was cal-
culated for each patient by fitting a linear regression of
monthly cost versus time, including a quadratic term,
and taking the coefficient for the quadratic term.
Utilization
InpatientDays The number of days spent in the
hospital.
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OfficeVisits The number of visits coded as 99213 or
99214 and taking place in an office or outpatient hos-
pital setting.
InpatientPerOffice The ratio of inpatient days to office
visits.
ERPerOffice The ratio of emergency room visits to
office visits.
TotalVisits The sum of the number of office visits,
emergency room visits, and inpatient days.
ERVisits.normalized ERVisits divided by TotalVisits.
InpatientDays.normalized InpatientDays divided by
TotalVisits.
OfficeVisits.normalized OfficeVisits divided by
TotalVisits.
ER.outpatient When an emergency room visit occurs, the
percent of time that the next visit is an outpatient visit.
ER.inpatient When an emergency room visit occurs, the
percent of time that the next visit is an inpatient visit.
ER.ER When an emergency room visit occurs, the per-
cent of time that the next visit is another emergency
room visit.
ER.Other When an emergency room visit occurs, the
percent of time that the next visit is any other type of
visit than outpatient, inpatient, or emergency.
DaysSinceLastERVisit The number of days between the
patient’s last emergency room visits and the end of the
study period. For patients who didn’t have any emer-
gency room visits this was set equal to the length of the
study period.
PhysicalTherapy The number of days on which the pa-
tient had physical therapy performed. (When a patient
has physical therapy it often lasts a large number of days
and this may drive up some of the quantity of care
measures).
Chiropractic The number of days in which the patient
had chiropractic services performed. As with physical
therapy, chiropractic is usually performed a large num-
ber of times and this may drive up some of the quantity
of care measures.Ratios
GenericLabsPerOffice GenericLab divided by
OfficeVisits
CostDrugRatio The patient’s median monthly cost divided
by the average number of chronic drugs they were on.
InpatientDrugRatio The number of days the patients
spent in the hospital divided by the average number of
chronic drugs they were on.
DiseaseVisitsRatio The number of chronic diseases di-
vided by the number of visits.
DiseaseRegularityRatio The number of chronic dis-
eases divided by VisitRegularity (see below).Markers of good care
The following variables correspond to aspects of the pa-
tient’s care that are considered to be markers of good care.
Mammogram The number of mammograms.
BinaryMammogram 1 if the patient had at least one
mammogram, 0 otherwise.
VisitRegularity The study period was broken up into
three-month intervals and VisitRegularity is the fraction
of those intervals in which there was at least one claim.
OfficeVisitRegularity The same as VisitRegularity ex-
cept that only office visits are counted, not all claims.
LongestOfficeGap The longest gap, in days, between
successive office visits.
Markers of poor care
Narcotics The number of prescriptions for narcotics.
NarcoticsDays The number of days for which the pa-
tient had narcotics prescribed.
B12 The number of prescriptions or injections of vita-
min B12. (Over-the-counter use of vitamin B12 would
not be included if the patient paid for out of their own
pocket.)
Polypharmacy An indicator variable which is 1 if the
patient’s pharmaceutical treatment for diabetes was initi-
ated with a combination of drugs at once. By default, the
indicator is set to 0 for patients who were already on
diabetes drugs at the beginning of the study period.
Providers
ProviderCount The number of providers that served
the patient. Note that along with physicians, a hospital,
lab, or a clinic can be counted as a provider, as can anes-
thesiologists, pathologists, etc.
PrescriberCount The number of doctors who pre-
scribed drugs for the patient.
DiabetesProviders The number of providers who
treated the patient’s diabetes. We include all providers
who had a claim for which diabetes was listed as the
diagnosis.
PrescribersPerProvider The number of prescribers di-
vided by the number of providers.
Claims
MedicalClaims The number of days on which the patient
had a medical claim (i.e. all claims except prescriptions).
ClaimLines The number of medical claims. This differs
from MedicalClaims in that multiple claims on the same
date are each counted.
ClaimsPerDate A patient may have multiple claims on
any given date. This is the total number of claims a pa-
tient had divided by the number of dates on which the
patient had claims. This variable is an attempt to tease
out the “complexity” of a visit – presumably the more
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Prescriptions
DrugsStarted The number of drugs started during the
study period. (Any drug for which the first prescription
occurs within the first 90 days of the study period is not
included since it is likely that the patient was already on
the drug and is renewing their prescription.)
DrugsEnded The number of drugs stopped during the
time period. (Any drug for which the last prescription
occurs within the last 90 days of the study period is not
included because the patient may have continued on the
drug after the study period ended.)
DrugsAtBeginning The number of drugs the patient is
on at the beginning of the time period. (Any drug for
which the first prescription occurs within the first 90
days of the study period is included here.)
MaxDrugs The maximum number of drugs the patient
was on at one time.
AverageDrugs The average number of drugs the patient
was on at a time
UniqueDrugs The number of distinct drugs that the pa-
tient was one over the course of the study period.
DrugGapNone The fraction of refills which occurred
immediately after the previous prescription ran out
(i.e. there was no gap before the refill).
DrugGapSmall The fraction of refills which were pre-
ceded by a small gap (between 1 and 30 days) after the
previous prescription ran out.
DrugGapMedium The fraction of refills which were
preceded by a medium gap (between 31 and 90 days)
after the previous prescription ran out.
DrugGapLarge The fraction of refills which were pre-
ceded by a large gap (more than 90 days). These likely
aren’t refills at all but indicate that the patient went off
of the medication for a while.
We included three versions of each prescription vari-
able: one version applies to all drugs, one applies only to
chronic drugs, and one only to acute drugs. The versions
applying to chronic drugs are prefixed “Chronic” and
those applying to acute drugs are prefixed “Acute.”
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